aflibercept

You have access
Risk–benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line Treatment in Metastatic Colorectal Cancer
MICHIO KIMURA, EISEKI USAMI, HITOMI TERAMACHI and TOMOAKI YOSHIMURA

Anticancer Research June 2021, 41 (6) 3091-3097; DOI: https://doi.org/10.21873/anticanres.15093
You have access
Impact of Anti-angiogenic Agents on Chemotherapy Efficacy in Patients With Metastatic Colorectal Cancer: Second-line FOLFIRI Plus Bevacizumab or Aflibercept
YUNAMI YAMADA, NOBUHISA MATSUHASHI, HIRONORI FUJII, AKITAKA MAKIYAMA, HIROTOSHI IIHARA, TAKAO TAKAHASHI, DAICHI WATANABE, SHIGERU KIYAMA, RYO KOBAYASHI, AKIO SUZUKI and KAZUHIRO YOSHIDA

Anticancer Research January 2021, 41 (1) 533-541; DOI: https://doi.org/10.21873/anticanres.14805
You have access
Chemoembolization in Colorectal Liver Metastases: The Rebirth
GIAMMARIA FIORENTINI, CAMILLO ALIBERTI, LUCA MULAZZANI, PAOLO COSCHIERA, VINCENZO CATALANO, DAVID ROSSI, PAOLO GIORDANI and STEFANO RICCI

Anticancer Research February 2014, 34 (2) 575-584;
You have access
Is there a Benefit from Addiction to Anti-VEGF Therapy in Patients with Colorectal Cancer?
MUHAMMAD WASIF SAIF

Anticancer Research June 2013, 33 (6) 2377-2380;

Main menu